Anaveon is open for collaborations with biotechnology, pharmaceutical,  and other therapeutics partners to discover, develop and commercialize innovative treatments in the fields of oncology (including immuno-oncology) and immune-related disorders.  We welcome opportunities to partner through in- and out-licensure, co-development, region-specific agreements, joint ventures, and other collaborations.

Our company’s strengths include:



  • cutting-edge science with a tailored approach and a focus on biologic therapeutics and immunology


  • rapid execution from drug design and discovery through preclinical and clinical development


  • cross-functional team with decades of experience with multiple indications in large pharma, specialty therapeutics and entrepreneurial biotechs


  • in-house laboratories, CMC development expertise, and broad clinical strategy and operations capabilities


  • world-renowned scientific advisors, top-tier investors, quality heritage, honest and collaborative values


If you wish to learn more about collaborating with Anaveon, please contact us:

Anaveon has entered into a clinical trial collaboration and supply agreement with MSD, to evaluate Anaveon’s wholly-owned drug candidate ANV600 in combination with KEYTRUDA in clinical trials. Under the terms of the agreement, MSD will supply KEYTRUDA. Anaveon retains all worldwide rights to ANV600.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
Our website uses cookies to provide you with the best online experience. By using our website, you accept the use of cookies in accordance with our Privacy Policy.